The World's first HoloGRAFT™ demo at Children´s Hospital of Philadelphia

The HoloGRAFT™ kit, developed by JETA Molecular in cooperation with Omixon, detects cell-free, donor-derived circulating DNA as a biomarker of organ health after transplantation using the highly sensitive digital PCR (dPCR) technology. On April 11, 2022, the dPCR experts from JETA Molecular organized the World´s first demo at Children´s Hospital of Philadelphia (CHOP), US, using the QIAcuity Digital PCR System.

We have demonstrated the 4-colour genotyping on the 24-well 8.5K nanoplates, followed by a monitoring (quantification) using the high density 26K nanoplates. According to the CHOP research team, HoloGRAFT™ represents a promising tool for routine monitoring of graft damage after transplantation to supplement invasive biopsies.